Complement inhibitors and plasma exchange therapy are equally safe and effective for atypical hemolytic uremic syndrome (aHUS), but complement inhibitors like Soliris (eculizumab) and Ultomiris (ravulizumab-cwvz) offer an edge in preventing relapses, especially in children, according to a new pooled analysis of real-world data. The analysis reveals…
A 4-year-old boy developed post-infectious glomerulonephritis (PIGN) and later atypical hemolytic uremic syndrome (aHUS), both of which affect the kidneys, but once doctors started treatment with the complement inhibitor Soliris (eculizumab), his blood problems resolved, his kidney function recovered, and he achieved long-term remission. “This case shows that…
Becoming educated and informed about aHUS is a good first step. Here you’ll find general information about the disease, including diagnosis, symptoms, and causes.
It helps to know others have been where you are now. Here’s a collection of our columnist’s words of wisdom to help you along on your aHUS journey.
There is no cure for aHUS yet, but here you can find more information about current therapeutic approaches, as well as experimental treatments that are in the pipeline.
Get regular updates to your inbox.
